Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction

Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and classic signaling, which also has anti-inflammatory effects. The novel recombinant fusion protein sgp130Fc achieves exclusive...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Marc Jonathan, Jasmin, Nur Hayati, Cummings, Valerie Taylor, Richard-Loendt, Angela, Launchbury, Francesca, Woollard, Kevin, Turner-Stokes, Tabitha, Garcia Diaz, Ana Isabel, Lythgoe, Mark, Stuckey, Daniel James, Hingorani, Aroon Dinesh, Gilroy, Derek William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Preclinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165121/
https://www.ncbi.nlm.nih.gov/pubmed/34095633
http://dx.doi.org/10.1016/j.jacbts.2021.01.013
Descripción
Sumario:Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and classic signaling, which also has anti-inflammatory effects. The novel recombinant fusion protein sgp130Fc achieves exclusive trans-signaling blockade, whereas anti–IL-6 antibodies (Abs) result in panantagonism. In a rat model of reperfused MI, sgp130Fc, but not anti–IL-6-Ab, attenuated neutrophil and macrophage infiltration into the myocardium, reduced infarct size, and preserved cardiac function 28 days after MI. These data demonstrate the efficacy of exclusive IL-6 trans-signaling blockade and support further investigation of sgp130Fc as a potential novel therapy in MI.

Ejemplares similares